Moreover, between 16 and 20% of all breast cancers are amplified for the HER2 proto-oncogene; these tumours in general belong to the so-called “HER2” class, again characterized by a distinct gene expression profile [1]. This evidence concerns the gene ERBB2 and breast carcinoma.